CAR T-Cell Therapy's Future in Multiple Myeloma: Mounzer Agha, MD
The director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center discussed the phase 2 CARTITUDE-2 trial.
Targeting CNS Disorders With Precision Gene Editing
The head of neuroscience at Sangamo Therapeutics discussed advances in understanding disease biology that allow for more specific gene targeting.
Second-Line Axi-Cel Improves Event-Free Survival Over Standard Care in LBC Lymphoma
The phase 3 ZUMA-7 trial met both its primary and secondary endpoints.
CAR T-Cell Therapy for Hematologic Cancers: Michael Bishop, MD
The professor of medicine and director of the Hematopoietic Stem Cell Transplantation Program at University of Chicago Medicine described the impact of CAR T-cell therapy on the hematologic cancer landscape.
Omidubicel Shows Efficacy Over Standard Umbilical Cord Blood Transplant in Hematologic Malignancies
Patients receiving omidubicel also spent less time in hospital following transplant.
Precision Gene Editing With Zinc Finger Protein Technology
The head of neuroscience at Sangamo Therapeutics discussed the potential of ZFPs in central nervous system disorders.
Celularity Expands Natural Killer Cell Therapy Trial to Relapsed/Refractory AML Following Patient Conversion
Conversion from MRD positivity to MRD-negative disease in a high-dose patient prompted the expansion of the trial population.
Financial Barriers Remain Despite Increased CAR T-Cell Referrals
Surveyed oncologists supported the use of CAR T-cell therapy at higher rates than previous years.
Novel Immunotherapy Enables CAR T-Cell Therapy in Solid Tumors
A novel combination immunotherapy enables CD19-directed CAR T-cell therapies to target and eradicate difficult-to-treat solid tumors.
Mechanism of VB-111 in Treating Ovarian Cancer: Bradley Monk, MD, FACOG, FACS
Bradley Monk, MD, FACOG, FACS, discusses the mechanism of VB-111 in patients with ovarian cancer.
EU CHMP Gives Positive Opinion for Ide-Cel's Use in Multiple Myeloma
The recommendation comes after positive data was released from the recent phase 2 KarMMa trial.
CRISPR Gene Editing for Transthyretin Amyloidosis Safe, Effective
Interim data from a phase 1 study from Intellia Therapeutics and Regeneron Pharmaceuticals is the first to support in vivo CRISPR genome editing in humans.
Promising Outlook in Multiple Myeloma with Cilta-Cel: Philippe Moreau, MD
Philippe Moreau, MD, discussed the CARTITUDE-1 trial's promising results with ciltacabtagene autoleucel read out at the 2021 ASCO Annual Meeting.
Safety Profile of Cilta-Cel: Saad Z. Usmani, MD, MBA, FACP
The director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute discussed adverse events in the CARTITUDE-1 trial.
Optogenetic Monotherapy for Retinitis Pigmentosa IND Approved, Phase 2b Study Enrolling
The announcement follows positive results from the phase 1/2a trial of MCO-010 for RP.
ATA188, a Cell Therapy for Progressive MS: Jakob Dupont, MD, MA
The head of global research and executive vice president of Atara Biotherapeutics discussed the development of ATA188.
Tackling Storage and Logistical Challenges in Cell Therapy
The chief executive officer of Gamida Cell discussed upcoming research on 2 of their investigational agents, GDA-201 and omidubicel, for hematological malignancies.
uniQure Expands Neurological Gene Therapy Pipeline With Epilepsy Program Acquisition
Corlieve Therapeutics’ lead program, AMT-260, previously demonstrated proof-of-concept in preclinical studies of temporal lobe epilepsy.
The Need for Novel Options in High-Risk Mantle Cell Lymphoma
Peter Riedell, MD, discussed the need for more research in mantle cell lymphoma and access to novel treatments, including CAR T-cell therapies.
Harnessing Gene Therapy for Osteoarthritis
Flexion Therapeutics believes that local administration of a gene therapy may not only improve pain management but potentially slow disease progression.
Gene Therapy for Hemophilia B Efficacious, Well-Tolerated
uniQure announced positive results from their phase 3 HOPE-B study of etranacogene dezaparvovec.
Presymptomatic Zolgensma Treatment Yields Age-Appropriate Development in SMA
Newly published data continues to demonstrate Zolgensma's efficacy in presymptomatic and symptomatic SMA Type 1.
Improving Bone Marrow Transplant With Omidubicel
The chief executive officer of Gamida Cell discussed the company's novel approach to cell proliferation.
New Collaboration to Evaluate Lower-Dose Gene Therapy Conditioning for Sickle Cell Disease
Jasper Therapeutics and Aruvant Sciences are studying the use of JSP191 used with ARU-1801 in patients with sickle cell disease.
Car T-Cell Therapy: The Future of Multiple Myeloma Treatment?
C. Ola Landgren, MD, PhD, discussed the role of CAR T-cell therapies in multiple myeloma.
The Potential of CAR T-Cell Therapy for Multiple Myeloma
James Hoffman, MD, discussed the significance of the approval of ide-cel for patients with multiple myeloma.
CAR T-Cell Therapy for Early-Relapsed Multiple Myeloma
Faith E. Davies, MD, discussed the potential of CAR T-cell therapies for the treatment of multiple myeloma.
Longer Follow-Up Shows Cilta-Cel Induces Deep, Durable Responses in Relapsed/Refractory MM
At the 18-month follow-up, the CAR T-cell therapy led to early, deep, and durable responses with a manageable safety profile in patients with relapsed/refractory multiple myeloma.
Broadening Gene Therapy's Reach With Novel Capsids
LogicBio's Mariana Nacht, PhD, shares details of the company's novel capsid discovery platform and gene editing technology.
Gene Therapies for ALS, Friedreich’s Ataxia the Focus of New CRISPR, Capsida Partnership
The news comes after CRISPR’s favorable data readouts in its sickle cell and beta thalassemia studies.
